Overview

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamics
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Nintedanib